Posts tagged CLRB
Ladenburg starts Cellectar Biosciences at buy

Ladenburg Thalmann launched coverage of Cellectar Biosciences (NASDAQ:CLRB) with a “buy” rating and $2.70 price target. The stock closed at $1.24 on Dec. 20.

Read More
Cellectar posts new positive data in Phase 1 MM trial

Cellectar Biosciences (NASDAQ:CLRB) reported positive data from the second cohort of patients enrolled in its orphan-drug designated Phase 1 study of CLR 131 in patients with relapsed or refractory multiple myeloma.

Following these outcomes, the study's data monitoring committee approved patient enrollment to the third cohort, which will include a 33% dose increase from the previous cohort.

Read More